Forty-four adult BMT recipients transplanted from an HLA-identical sibling donor were randomized to receive meningococcal polysaccharide (Men PS) vaccine either 8 (early group; 22 patients) or 20 (late group; 22 patients) months after BMT. The geometric mean concentrations (GMC) of antibodies to serogroup A Neisseria meningitidis (Men A) and serogroup C Neisseria meningitidis (Men C), determined by an EIA method, decreased during the first 6 months after BMT but remained at a stable level thereafter. Before vaccination the GMCs of anti-Men A were 1.53 g/ml and 1.61 g/ml, but 1 month after vaccination they were significantly higher, 3.46 g/ml and 6.39 g/ml, in the early and late groups. The GMCs of anti-Men C increased from 0.37 g/ml and 0.44 g/ml before vaccination to 3.31 g/ml and 4.62 g/ml at 1 month after vaccination in the early and late groups, respectively. By 6 months after vaccination the GMCs of Men antibodies had decreased to levels of about 50% of those measured at 1 month after vaccination. Two-fold responses to Men A PS were seen in 52% and 74% and to Men C PS in 76% and 89% of the BMT recipients in the early and late groups, respectively. Chronic GVHD had no influence on the vaccination response. In the present study, Men PS vaccine induced good and equal antibody responses to Men A and Men C PSs in allogeneic BMT recipients regardless of timing after BMT. Vaccination against Neisseria meningitidis should be considered, especially in the event of travelling or military service у8 months after BMT. Bone Marrow Transplantation (2001) 27, 79-84. Keywords: vaccination response; BMT recipients; meningococcal antibodies Neisseria meningitidis (Men) is a major cause of bacterial meningitis in North America and Europe.
(Men C), and a shift in the age distribution away from young children. 3 Serogroup B and C strains cause most of the Men diseases in the developed world, for example in the UK, whereas serogroup A (Men A) predominates in sub-Saharan Africa. In 1996 in England and Wales 40% of the Men disease cases were caused by serogroup C, 4 and in Finland 13% of 54 cases of the invasive meningococcal diseases in 1998 were of serogroup C. 5 Although Men vaccines containing Neisseria meningitidis serogroup A and C polysaccharides (PS) have been available for a long time, their routine use has not been recommended, since the vaccines have been poorly immunogenic in infants and toddlers and the immune response to serogroup C has been short-lived in young children. [6] [7] [8] [9] For group B there is no polysaccharide vaccine available due to its poor immunogenicity even in adults.
Allogeneic BMT recipients are immunodeficient for months to years after transplantation. [10] [11] [12] [13] The ability to respond to PS antigens matures slowly after BMT, and the responses to vaccinations with pneumococcal PS and Haemophilus influenzae type b PS vaccines have been poor [14] [15] [16] [17] [18] [19] [20] [21] and the ability of pneumococcal PS vaccine to prevent infections limited. 14, 22 Patients undergoing allogeneic BMT from an HLAidentical sibling donor show a favourable outcome; longterm survival figures range from 50 to 80%. [23] [24] [25] Two thirds of Finnish adult allogeneic BMT recipients are working or studying 1 year after BMT. 26 These healthy long-term survivors may travel to areas of higher incidence of Neisseria meningitidis or may be exposed in higher risk closed groups, for example as conscripts in the army.
The aim of the present study was to to find out in a randomized study whether Men PS vaccine given at 8 or 20 months after BMT is immunogenic in adult allogeneic BMT recipients and whether it could be expected that immunization of BMT recipients confers protection against infections caused by serogroup A and C Neisseria meningitidis.
Materials and methods

Patients and vaccinations
Forty-four consecutive adult (age у16 years) BMT recipients who received a non-T cell-depleted bone marrow transplant from an HLA-identical sibling donor at Helsinki University Central Hospital were randomly vaccinated with Men PS vaccine (Mencevax ACW 135 Y, Smith Kline-RIT, Rixensart, Belgium) either 8 (early group) or 20 (late group) months after BMT. The study protocol, patient characteristics, and other vaccines used in immunizations have been described in detail earlier. 21 Briefly, 22 patients were immunized at 8 months after BMT and 22 patients at 20 months after BMT with Men PS vaccine containing 50 g Men group A, C, W 135 , and Y PSs. The recipients with haematological malignancies were conditioned with cyclophosphamide and TBI (17 patients in the early and 19 in the late group) or cyclophosphamide and busulphan (four patients in the early and three in the late group). Four patients with CML also received one infusion of daunorubicin, 60 mg/m 2 and splenic irradiation. The patient with aplastic anaemia was conditioned with cyclophosphamide 50 mg/kg on 4 consecutive days and with total nodal irradiation 8.0 Gy in four fractions on 2 consecutive days. Thirteen patients in the early group and 13 in the late group had acute GVHD. Acute GVHD was treated with methylprednisolone, starting with a dose of 2 mg/kg/day or 10-15 mg/kg/day, depending on the severity of GVHD. Twelve patients in the early group and nine patients in the late group had clinical symptoms or signs of chronic GVHD after BMT. Chronic GVHD was treated with methylprednisolone alone or in combination with azathioprine or thalidomide.
Serum samples
One blood sample was drawn from the patients before starting conditioning for BMT. Before starting Men PS vaccinations blood samples were collected at 2-month intervals until 6 months after BMT, and thereafter in the late group at 6-month intervals until 18 months. Vaccination responses were determined in the sera collected from the early group patients at 8 and 9 months and from the late group patients at 20 and 21 months after BMT (immediately before vaccination and 1 month after vaccination). Follow-up samples were collected at 6, 12, 16 and 28 months after vaccination. One blood sample was taken from the donors before bone marrow harvest.
EIA for Men antibodies
An enzyme immunoassay (EIA) method 27 was used to quantify antibody responses to serogroup A and C Men capsular PSs. The EIA plates (Immunolon; Dynatech Laboratories, Chantilly, VA, USA) were coated with Men A and Men C received from Dr Patrick McVerry (Connaught Laboratories, Swiftwater, PA, USA) mixed with methylated human serum albumin. 28 The serum samples and peroxidase-conjugated goat anti-human immunoglobulin (P212 Dakopatts, Copenhagen, Denmark) were diluted in phosphate-buffered saline containing 10% fetal calf serum. A pool of sera from adults immunized with tetravalent Men vaccine was used in all determinations as a standard. This pool contained 25 g/ml and 28 g/ml antibodies to Men A and Men C, respectively, as determined by comparison by radioimmunoassay with ECG reference serum. Later, the in-house reference was related to the new international reference CDC1992, 29 and thus the final results are adjusted to that reference. The lower detection limits were 0.74 g/ml for Men A PS antibodies and 0.25 g/ml for Men C PS antibodies. For calculations, sera with undetectable concentrations of anti-Men A PS or anti-Men C PS were assigned the lower detection limits of the antibody assay. The Men PS antibody concentrations required for protection against group A and C Men disease have not been determined directly but have been estimated indirectly to be in the order of 1-2 g/ml.
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Statistical methods
The antibody concentrations were transformed to logarithms for statistical calculations. Paired t-test was used to compare the geometric mean concentrations (GMC) of Men PS antibodies before and 1 month after vaccination. t-Test for two independent samples was used to compare the GMCs of Men antibodies between the two vaccination groups. Fisher's exact test was used to compare the frequency of patients in the two vaccination groups with two-and four-fold antibody responses to vaccinations.
Results
The GMCs of Men A and Men C PS antibodies decreased after BMT, especially during the first 6 months (Figures 1  and 2 ). Thereafter, the specific antibody concentrations remained at a relatively stable level in the late group in which they could be followed until 20 months after BMT before starting vaccinations. The GMCs of anti-Men A PS and anti-Men C PS were significantly higher 1 month after vaccination than before vaccination in both vaccination groups ( Table 1 ). The duration of the response was shortlived; 6 months after immunization the antibody concentrations had decreased to levels of about 50% of those measured at 1 month after vaccination (Figures 1 and 2) , and 28 months after vaccination the GMCs of anti-Men A PS and anti-Men C PS were similar to those before vaccination. There were no statistically significant differences in the GMCs of the antibodies to Men A and Men C PSs between the two vaccination groups either before, or 1, 6, 12, 16 and 28 months after vaccination. Before transplantation 37 (90%) and 18 (44%) out of 41 donors and 32 (84%) and 14 (37%) out of 38 recipients with serum samples had anti-Men A PS and anti-Men C PS concentrations у1 g/ml, respectively. The proportions of patients with anti-Men A and anti-Men C concentrations у1 g/ml decreased after BMT, and only 10% of the late group patients had anti-Men C concentration у1 g/ml at 20 months after BMT before vaccination (Table 1) . One month after vaccination 76-89% of the patients showed Men antibody concentrations у1 g/ml (Table 1) . Twelve months after vaccination 61% of the early group patients had anti-Men A and anti-Men C concentrations у1 g/ml, and 73% and 53% of the late group patients showed antiMen A and anti-Men C concentrations у1 g/ml, respectively. Still at 28 months after immunization 82% and 71% of the early and late group patients had anti-Men A concentrations у1 g/ml, but only 45% and 43% of the recipients showed anti-Men C concentrations у1 g/ml, respectively. The proportions of patients with Men antibody concen- trations у2 g/ml, the higher estimated level for protection, before and after vaccination are also presented in Table 1 . The frequency of two-fold responses to Men A and Men C PSs was similar in the two vaccination groups (Table 1) . Four-fold responses to Men A PS were seen more often in the late group patients (9/19) than in the early group patients (3/21; P = 0.04).
Patients in the early group with previous acute GVHD had lower GMC of Men A PS antibodies 1 month after vaccination compared to patients without acute GVHD (2.03 g/ml versus 7.06 g/ml; P = 0.02). Otherwise the GMCs were similar in the patients with and without acute GVHD. In the early group, at 1 month after vaccination the GMCs of anti-Men A and anti-Men C were 3.33 g/ml and 2.76 g/ml in the nine patients with and 3.57 g/ml and 3.79 g/ml in the 12 patients without clinically active chronic GVHD within 2 months prior to or at the time of vaccination, respectively. In the late group at 1 month after vaccination the GMCs of anti-Men A and anti-Men C were 14.22 g/ml and 9.30 g/ml in the five patients with and 4.80 g/ml and 3.60 g/ml in the 14 patients without chronic GVHD, respectively.
Discussion
The present study shows that a large proportion of allogeneic BMT recipients vaccinated у8 months after transplantation with a tetravalent Men PS vaccine produces good antibody responses to Men A and Men C PSs. In contrast, the responses to vaccinations with another PS vaccine, pneumococcal PS vaccine, have been extremely poor after BMT, 14, 15, [17] [18] [19] [20] [21] leading to the recommendation to give pneumococcal PS vaccine to stem cell transplant recipients but not to trust that the efficacy of the vaccine can prevent pneumococcal infections. 31, 32 The BMT recipients in the present study were transplanted with non-manipulated grafts with the exception of the removal of red cells and plasma in cases of ABO incompatibility. This is in contrast to the only previous study on the immunogenicity of Men PS vaccine after allogeneic BMT in which 13 BMT recipients conditioned with a regimen containing antilymphocyte globulin, procarbazine, cyclophosphamide, and TBI and transplanted with a T cell-depleted marrow from a sibling donor produced no IgG antibodies after vaccination with Men PS vaccine 7-15 months after transplantation. 33 However, significant IgM responses were seen. Antilymphocyte globulin treatment and T cell-depletion of the graft delay the recovery of immunological reactivity. 12, 34 In the BMT recipients of the present study the GMCs of antibodies to Men A and Men C PSs were significantly higher 1 month after than before immunization with Men PS vaccine regardless of the time of vaccination, at 8 or 20 months after BMT. In healthy infants Men A PS vaccine has induced significant increases in the GMCs of anti-Men A PS already from 7 months of age and Men C PS vaccine as early as at 3 months of age. 6, 35 However, the responses have only been about 2% of those in adults. Group A and C protein conjugate vaccines have been tested in clinical trials and they have proven immunogenic even in infants and children. [36] [37] [38] In the present BMT recipients the GMCs of antibodies to Men A and Men C PSs declined sharply over the first 6-12 months after vaccination, in a similar way as anti-capsular and bactericidal antibodies to Neisseria meningitidis group A and especially to group C in young children. [7] [8] [9] In healthy adolescents and adults anti-Men A and Men C concentrations have persisted for at least 4-10 years after immunization. 35, 39, 40 Thus, although Men PS vaccine seems to be immunogenic enough to induce a short-lived antibody response in allogeneic BMT recipients, BMT recipients resemble young children in their poor capability to retain Men PS antibody concentrations. Re-vaccinations should be considered if a new or continuous risk of exposure to Men infection occurs after primary vaccination.
Antibody concentrations у1-2 g/ml against Men PSs have been estimated to be protective against invasive Men diseases. 30 Only 10% of the BMT recipients had anti-Men C concentration у1-2 g/ml before vaccination but 76-84% achieved this level 1 month after vaccination. The proportion of the BMT recipients in the present study, on average 80%, attaining the anti-Men C PS concentration у2 g/ml is slightly higher than the 68% of infants vaccinated with Men PS vaccine at the age of 6-11 months. 9 Men PS vaccine has been recommended to children у6-24 months of age if indicated by, for example, functional or anatomic asplenia or when travelling or residing in countries with hyperendemic or epidemic meningococcal diseases caused by vaccine-preventable serogroup meningococci. 9, 41 Many BMT recipients are healthy and working at 8 months after BMT and may want to travel abroad. In the light of the present results, Men PS vaccine should be given to allogeneic BMT recipients who have survived у8 months after transplantation, if indicated by, for example, travelling, military service or studying and living on a university campus. On the other hand, functional asplenia found especially in BMT recipients with chronic GVHD 42 may be an important further indication for immunizing BMT recipients with Men PS vaccine.
The response to the late vaccination with Men PS vaccine was not markedly better than the response to the early vaccination. After the immunization, the GMCs of Men A and Men C PS antibodies, the proportions of patients achieving Men PS antibody concentrations у1 g/ml, and the proportions of patients with two-and four-fold responses were similar in the early and late vaccination groups, with only one exception; four-fold responses to Men A PS occurred more frequently in the late group patients than in the early group patients. The early group patients with previous acute GVHD showed lower antiMen A PS response compared to the BMT recipients without acute GVHD. At 8 months after transplantation immunosuppression caused by acute GVHD and also its treatment may be more severe than at 20 months after BMT. At least in the present study the antibody responses to Men A PS were slightly lower than the responses to Men C PS, and therefore anti-Men A responses may be more vulnerable to immunosuppression caused by GVHD.
In conclusion, allogeneic BMT recipients show good antibody responses to Men A and Men C PSs after immuni-zation with Men PS vaccine. The schedule of vaccination, at 8 or 20 months after BMT, has no influence on the response. Chronic GVHD does not seem to impair the vaccination response but may rather be an additional indication for immunization with Men PS vaccine.
